Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals is viewed positively because its commercial base is proving resilient across multiple franchises, with 3Q26 revenue of $1.243B beating expectations and the sleep portfolio still generating $552M in the quarter while Xywav rose 12% YoY to $483M with about 17,550 active patients. The outlook is further strengthened by oncology momentum, as Ziihera delivered $21M in sales in its first quarter after HER2+ GEA approval with management now framing $3B to $5B of peak potential, while Zepzelca, Rylaze, Vyxeos, and Epidiolex diversify cash flow and reduce reliance on Xyrem. Financially, guidance was raised to $4.6B to $4.75B for FY26 and management indicates expenses are controlled, supporting EPS growth as commercial execution and pipeline catalysts, including Modeyso and JZP6979, add optionality.

Jazz Pharmaceuticals is facing a negative fundamental setup because its core narcolepsy franchise looks vulnerable to erosion from generic Xyrem, Lumryz expansion, and orexin competition, even as the broader oxybate business is expected to stay largely flat in 2027 at about $2.06B. The company also carries meaningful regulatory and clinical risk across the pipeline, including possible negative Phase 3 results for Zepzelca and uncertain readouts for early programs such as JZP150 and JZP385, while reimbursement and FDA approval risks could further constrain growth. In addition, Epidiolex may face generic competition as early as after expiration of ODE in 2027, and oncology remains a highly competitive, high-risk area that limits visibility on durable upside.